Because PD-L1 in CCA is predominantly derived from tumor-associated macrophages (TAMs), PD-1 blockade can be enhanced by targeting tumor-associated macrophages and granulocyte-myeloid-derived suppressor cells (55). This evidence concerns the gene PDCD1 and cholangiocarcinoma.